Adamax research monograph — the Semax/P021 hybrid designer peptide

Adamax is a synthetic designer peptide that has appeared in research-vendor catalogues and on regulator desks over the last several years. Unlike most compounds in this catalogue, Adamax has essentially no direct peer-reviewed pharmacology literature of its own — the published characterisation rests entirely on its two parent compounds, Semax and Peptide 021 (P021). This monograph lays out what Adamax actually is at the chemical level, what its inferred pharmacology would be from its parents, what the regulatory record looks like, and — equally important — what the evidence record does not contain.

Chemical identity and structure.
Adamax is a single defined molecule with the sequence Ac-MEHFPGPAG-NH₂, molecular formula C₅₀H₆₉N₁₁O₁₁S, molecular weight 1032.23 g/mol. Structurally it is a hybrid: the MEHFPGP core is the Semax heptapeptide (an ACTH 4–10 analog), extended at the C-terminus by an adamantyl-glycine group taken directly from Peptide 021 (P021), the CNTF-mimetic developed by Iqbal and colleagues for Alzheimer's research. The N-terminal acetyl and C-terminal amide cap match the standard cap pattern used in both parent molecules. The adamantane cage — a rigid tricyclic hydrocarbon — is the structural feature the name derives from and is the modification that distinguishes Adamax from any plain Semax analog. Adamax is not a blend, despite some vendor catalogues categorising it as one; it is a single chemically-defined synthetic peptide.

Inferred mechanism of action.
No direct receptor or pathway studies on Adamax have been published in PubMed-indexed literature. The expected pharmacology is therefore inferred entirely from the parent compounds. From the Semax core, Adamax would be predicted to engage the ACTH 4–10 pharmacology axis: BDNF upregulation, TrkB-receptor sensitisation, dopaminergic-pathway effects, and the neuroprotective profile characterised in Semax cerebral-ischaemia models. From the P021-derived adamantyl-glycine modification, Adamax would be predicted to inherit P021's CNTF-mimetic effects (LIF-signalling inhibition, BDNF transcription enhancement) plus the resistance-to-degradation and improved blood-brain-barrier penetration the adamantyl group confers on small peptides. Whether these inferred mechanisms actually express in the combined molecule, and at what relative weights, has not been demonstrated — the hybrid could behave like Semax, like P021, like both, or like neither.

Research applications and the evidence base.
Direct peer-reviewed pharmacology, behavioural, or clinical studies on Adamax itself are absent from PubMed as of the writing of this monograph. The parent-compound evidence base is substantive: Semax has substantial Russian clinical literature including registered indications for stroke recovery and cognitive disorders in the Russian Federation; P021 has documented preclinical efficacy in 3×Tg-AD and Ts65Dn mouse models of Alzheimer's disease and Down-syndrome cognitive impairment. Anyone presenting Adamax research findings as "established" or "studied" is overstating the literature — the citations apply to the parents, not to the hybrid.

Regulatory status.
Adamax has been classified as a designer drug by New Zealand Medsafe (June 2025 "Classification of Unscheduled Peptides" submission to the Medicines Classification Committee), where it was identified in border seizures and subsequently scheduled as a prescription medicine for legal-control purposes. The compound is not registered as a pharmaceutical in any major jurisdiction known to VialTalk, and unlike Semax (registered in the Russian Federation) or methylene blue (FDA-registered for methemoglobinemia), Adamax has no approved therapeutic indication anywhere.

Research context.
Researchers encountering Adamax in vendor catalogues should treat it as a structural-pharmacology curiosity rather than a characterised research tool. The hybrid design — combining a Russian nootropic core with the C-terminal modifications of an Alzheimer's-research peptide — is conceptually interesting, but the absence of direct pharmacology data means inferences from the parent compounds carry the full epistemic weight. Research designs that depend on a well-characterised reference compound should use Semax or P021 directly; Adamax is not a substitute for either.

Storage and handling.
Lyophilized Adamax should be kept refrigerated (2–8 °C) and protected from light. Once reconstituted with bacteriostatic water, the solution is typically used within 14–30 days when refrigerated. The peptide tolerates refrigerator-temperature storage reasonably well but does not tolerate repeated freeze-thaw cycles. The lyophilized powder should appear white to off-white; the reconstituted solution should be colourless and clear.

Quality and COA considerations.
A meaningful COA for Adamax must confirm identity via mass spectrometry against the expected 1032.23 g/mol molecular weight (a value clearly distinct from plain Semax at ~813 g/mol), purity by HPLC (≥98% benchmark), and explicit disambiguation from both Semax and any other adamantyl-modified peptide analog. Vendor labelling has been inconsistent — some catalogues describe Adamax as a Semax + Selank blend, which is chemically incorrect. A competent COA should make the single-molecule identity unambiguous via the molecular-weight check alone.

Research-use note: This monograph is an educational summary of the chemical identity and inferred pharmacology of Adamax (Ac-MEHFPGPAG-NH₂). The compound has not been evaluated in any completed clinical trial, has no peer-reviewed pharmacology literature of its own, and has been classified as a designer drug by at least one national regulator (NZ Medsafe). Inferred mechanisms from Semax and Peptide 021 are speculative until directly demonstrated. Nothing here is medical advice or a usage recommendation.